We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
+4.72%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$123M
AUM Growth
+$5.7M
Cap. Flow
+$11.5M
Cap. Flow %
9.4%
Top 10 Hldgs %
64.1%
Holding
36
New
1
Increased
9
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$5.09M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$1.97M
3
OCS icon
Oculis Holding
OCS
+$1.61M
4
ARGX icon
argenx
ARGX
+$1.5M
5
REPL icon
Replimune Group
REPL
+$1.14M

Top Sells

Rank Stock Value
1
RBRK icon
Rubrik
RBRK
+$1.59M
2
ONC
BeOne Medicines Ltd
ONC
+$999K
3
INCY icon
Incyte
INCY
+$558K

Sector Composition

Rank Sector Weight
1 Healthcare 99.8%
2 Materials 0.2%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRMY icon
1
Harmony Biosciences
HRMY
$2.04B
$12.2M 9.98%
368,665
– –
OCS icon
2
Oculis Holding
OCS
$683M
$9.79M 7.99%
514,702
+78,324
+18% +$1.61M
ILMN icon
3
Illumina
ILMN
$31B
$9.46M 7.71%
119,196
– –
VRNA
4
DELISTED
Verona Pharma
VRNA
$9.4M 7.66%
147,990
+14,950
+11% +$894K
ZLAB icon
5
Zai Lab
ZLAB
$2.06B
$9.17M 7.48%
253,675
+18,675
+8% +$574K
MIRM icon
6
Mirum Pharmaceuticals
MIRM
$6.46B
$6.61M 5.39%
146,765
+21,435
+17% +$1.01M
PTGX icon
7
Protagonist Therapeutics
PTGX
$8.79B
$5.87M 4.79%
+121,400
New +$5.09M
SLNO
8
DELISTED
Soleno Therapeutics
SLNO
$5.69M 4.64%
79,650
– –
XENE icon
9
Xenon Pharmaceuticals
XENE
$6.06B
$5.32M 4.34%
158,605
+51,925
+49% +$1.97M
MRUS
10
DELISTED
Merus
MRUS
$5.05M 4.12%
120,038
– –
ONC
11
BeOne Medicines Ltd
ONC
$32.8B
$4.28M 3.49%
15,722
-4,275
-21% -$999K
REPL icon
12
Replimune Group
REPL
$941M
$4.04M 3.29%
414,246
+92,500
+29% +$1.14M
MDGL icon
13
Madrigal Pharmaceuticals
MDGL
$10.8B
$3.93M 3.21%
11,872
+750
+7% +$246K
INCY icon
14
Incyte
INCY
$24.2B
$3.57M 2.91%
59,022
-8,000
-12% -$558K
RXRX icon
15
Recursion Pharmaceuticals
RXRX
$1.59B
$3.52M 2.87%
664,610
– –
TRML
16
DELISTED
Tourmaline Bio
TRML
$3.45M 2.82%
227,090
+40,000
+21% +$641K
RYTM icon
17
Rhythm Pharmaceuticals
RYTM
$6.81B
$2.6M 2.12%
49,120
– –
EXEL icon
18
Exelixis
EXEL
$13.3B
$2.37M 1.93%
64,200
– –
GERN icon
19
Geron
GERN
$828M
$2.18M 1.78%
1,373,550
– –
ASND icon
20
Ascendis Pharma A/S
ASND
$16B
$2.12M 1.73%
13,600
– –
LAB icon
21
Standard BioTools
LAB
$340M
$2.03M 1.66%
1,883,179
– –
KALV
22
DELISTED
KalVista Pharmaceuticals
KALV
$1.78M 1.45%
154,522
– –
ACAD icon
23
Acadia Pharmaceuticals
ACAD
$4.43B
$1.71M 1.4%
102,984
– –
ARGX icon
24
argenx
ARGX
$54.6B
$1.66M 1.35%
2,800
+2,370
+551% +$1.5M
KYMR icon
25
Kymera Therapeutics
KYMR
$8.51B
$845K 0.69%
30,875
– –
1
2

Similar funds

TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Nan Fung Group Holdings's Q1 2025 Portfolio in Review

As of Q1 2025, Nan Fung Group Holdings held 36 positions worth $123M, up 4.9% from $117M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Nan Fung Group Holdings deployed $11.5M of net new capital in Q1 2025, opening 1 new position and adding to 9 existing holdings. Its largest new stake was Protagonist Therapeutics: 121,400 shares worth $5.87M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Materials and Technology.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $999K trimmed.

  • Nan Fung Group Holdings's largest Q1 2025 buy was Protagonist Therapeutics: 121,400 shares worth $5.87M.
  • Nan Fung Group Holdings added most to Xenon Pharmaceuticals in Q1 2025, an estimated $1.97M increase.
  • Nan Fung Group Holdings's biggest Q1 2025 reduction was BeOne Medicines Ltd, cutting an estimated $999K.
  • Nan Fung Group Holdings fully exited Rubrik in Q1 2025, selling an estimated $1.59M.
  • Nan Fung Group Holdings's ten largest holdings make up 64% of its $123M portfolio in Q1 2025.
  • Nan Fung Group Holdings opened 1 new position and closed 1 in Q1 2025.
  • Nan Fung Group Holdings's portfolio value rose 4.9% quarter-over-quarter to $123M.

Based on Nan Fung Group Holdings's 13F filing for Q1 2025, filed 14 May 2025.